

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **SciClone Pharmaceuticals (Holdings) Limited**

**賽生藥業控股有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6600)**

### **VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE**

#### **COMMERCIAL LAUNCH OF DANYELZA<sup>®</sup> (NAXITAMAB) IN CHINA**

This announcement is made by SciClone Pharmaceuticals (Holdings) Limited (the “**Company**” or “**SciClone Pharmaceuticals**”, together with its subsidiaries, the “**Group**”) on a voluntary basis. The purpose of this announcement is to keep the shareholders of the Company (the “**Shareholders**”) and potential investors informed on the latest business development of the Group.

The Company is pleased to announce that the Commercial Launch Conference of DANYELZA<sup>®</sup> (naxitamab) (“**DANYELZA<sup>®</sup>**”) was held on July 1, 2023. The first batch of prescriptions of DANYELZA<sup>®</sup> has been issued. With the official commercialization in China, the Company is well prepared to provide this new immunotherapeutic approach to patients with relapsed or refractory high risk neuroblastoma in China.

DANYELZA<sup>®</sup> is approved by the National Medical Products Administration (the “**NMPA**”) in China for the treatment, in combination with granulocyte-macrophage colony-stimulating factor (“**GM-CSF**”), of pediatric patients of 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.

Prior to the approval by the NMPA, benefitting from policy support in China, SciClone Pharmaceuticals pilot launched DANYELZA<sup>®</sup> in Hainan Bo’Ao Lecheng International Medical Tourism Pilot Zone and China (Tianjin) Pilot Free Trade Zone in June 2021 and December 2021, respectively. Since January 2022, SciClone Pharmaceuticals has been selling DANYELZA<sup>®</sup> in Taiwan based on local special import policy.

The Company is also actively seeking to expand the disease indications that may be addressed using DANYELZA<sup>®</sup>. For instance, the Company is preparing for studies aiming to explore the treatment of DANYELZA<sup>®</sup> in other solid tumors with high GD2 expression.

### **About the Company:**

SciClone Pharmaceuticals is a global biopharmaceutical company with an integrated platform for the development and commercialization of innovative therapies for cancer and severe infection. With an innovation-driven strategic transformation, SciClone Pharmaceuticals has established a product portfolio with differentiated advantages, including a number of first-in-class and best-in-class potential products/pipelines. Staying true to the Group's original aspiration of "SciClone gives life hope", SciClone Pharmaceuticals is dedicated to improving patients' health by providing top-tier healthcare products and services with global standards of care. For more information about the Company, please visit [www.sciclone.com](http://www.sciclone.com).

### **Definitions**

"China" the People's Republic of China; for the purposes of this announcement only and except where the context requires otherwise, excludes Hong Kong, Macau and Taiwan

By order of the Board  
**SciClone Pharmaceuticals (Holdings) Limited**  
**ZHAO Hong**  
*Executive Director, Chief Executive Officer and President*

Hong Kong, July 2, 2023

*As at the date of this announcement, the Board comprises Mr. Zhao Hong and Ms. Pan Rongrong as executive directors, Mr. Li Zhenfu, Dr. Daniel Luzius Vasella, Ms. Lin Shirley Yi-Hsien and Ms. Wang Haixia as non-executive directors, and Dr. Liu Guoen, Dr. Chen Ping, Mr. Gu Alex Yushao and Ms. Wendy Hayes as independent non-executive directors.*

\* *for identification purpose only*